 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1998 | Volume 129 Issue 12 | Pages 1027-1030
Background: Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased.
Objective: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacter pylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin.
Design: Prospective cohort study.
Setting: University hospital and health service center in Hamamatsu, Japan.
Patients: 62 patients with peptic ulcer and H. pylori infection.
Intervention: Omeprazole and amoxicillin.
Measurements: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer.
Results: Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection.
Conclusion: The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.
Author and Article Information
From Hamamatsu University School of Medicine and Honda Motor Co., Ltd., Hamamatsu, Japan; and SRL, Inc., and International Medical Center of Japan, Tokyo, Japan.
BRIEF COMMUNICATION
Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer
Acknowledgments: The authors thank Yasue Noda for PCR restriction fragment length polymorphism analysis of blood samples and thank endoscopy nurses Kiwako Tsuchiya, Miho Ijiri, Rie Suzuki, Tazuko Suzuki, Kayoko Imada, Terumi Yagi, and Emi Ichise for assistance.
Grant Support: By Grants-in-Aid for Scientific Research from the Ministry of Education of Japan (08570577 and 10672149).
Requests for Reprints: Takahisa Furuta, MD, First Department of Medicine, Hamamatsu University School of Medicine, 3600, Handa-cho, Hamamatsu 431-3192, Japan; e-mail, furuta@akiha.hama-med.ac.jp.
Current Author Addresses: Drs. Furuta, Takashima, Hanai, and Kaneko: First Department of Medicine, Hamamatsu University School of Medicine, 3600, Handa-cho, Hamamatsu 431-3192, Japan.
This article has been cited by other articles:
|
|
 |
|
  J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lofgren, R. M. Baldwin, M. Hiratsuka, A. Lindqvist, A. Carlberg, S. C. Sim, M. Schulke, M. Snait, A. Edenro, R. Fransson-Steen, et al. Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression Drug Metab. Dispos., May 1, 2008; 36(5): 955 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Court A Pharmacogenomics Primer J. Clin. Pharmacol., September 1, 2007; 47(9): 1087 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden, R. B. Altman, N. L. Benowitz, D. A. Flockhart, K. M. Giacomini, J. A. Johnson, R. M. Krauss, H. L. McLeod, M. J. Ratain, M. V. Relling, et al. Pharmacogenomics: Challenges and Opportunities. Ann Intern Med, November 21, 2006; 145(10): 749 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Devlin, L. S Welage, and K. M Olsen Proton Pump Inhibitor Formulary Considerations in the Acutely Ill Part 1: Pharmacology, Pharmacodynamics, and Available Formulations Ann. Pharmacother., October 1, 2005; 39(10): 1667 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Wilkinson Drug Metabolism and Variability among Patients in Drug Response N. Engl. J. Med., May 26, 2005; 352(21): 2211 - 2221. [Full Text] [PDF]
|
|
|
|
|
|
N. Yasui-Furukori, M. Saito, T. Uno, T. Takahata, K. Sugawara, and T. Tateishi Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes J. Clin. Pharmacol., November 1, 2004; 44(11): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Q. P. Yin, B. Tomlinson, A. H. L. Chow, M. M. Y. Waye, and M. S. S. Chow Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability J. Clin. Pharmacol., June 1, 2004; 44(6): 582 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Ma, A. N. Nafziger, and J. S. Bertino Jr. Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers J. Clin. Pharmacol., May 1, 2004; 44(5): 447 - 456. [Abstract] [Full Text]
|
|
|
|
|
|
D. F. Lehmann, J. J. Medicis, and P. D. Franklin Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer J. Clin. Pharmacol., December 1, 2003; 43(12): 1316 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. S. Ferguson, M. Negishi, and J. A. Goldstein Identification of Constitutive Androstane Receptor and Glucocorticoid Receptor Binding Sites in the CYP2C19 Promoter Mol. Pharmacol., August 1, 2003; 64(2): 316 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W E Evans Pharmacogenomics: marshalling the human genome to individualise drug therapy Gut, May 1, 2003; 52(90002): ii10 - 18. [Abstract] [Full Text]
|
|
|
|
|
|
R. Weinshilboum Inheritance and Drug Response N. Engl. J. Med., February 6, 2003; 348(6): 529 - 537. [Full Text] [PDF]
|
|
|
|
|
|
A. J.J. Wood Racial Differences in the Response to Drugs -- Pointers to Genetic Differences N. Engl. J. Med., May 3, 2001; 344(18): 1393 - 1396. [Full Text] [PDF]
|
|
|
|
|
|
M. Ingelman-Sundberg Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism for Drug Development Drug Metab. Dispos., April 1, 2001; 29(4): 570 - 573. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. M. Roden and N. J. Brown Preprescription Genotyping : Not Yet Ready for Prime Time, but Getting There Circulation, March 27, 2001; 103(12): 1608 - 1610. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shu, L.-S. Wang, Z.-H. Xu, N. He, W.-M. Xiao, W. Wang, S.-L. Huang, and H.-H. Zhou 5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 844 - 851. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Emilien, M. Ponchon, C. Caldas, O. Isacson, and J.-M. Maloteaux Impact of genomics on drug discovery and clinical medicine QJM, July 1, 2000; 93(7): 391 - 423. [Abstract] [Full Text] [PDF]
|
|
Article
